October 24th, 2019 Natixis Partners advised Meeschaert Capital Partners in the disposal of Sterimed to Sagard

Three years after investing in Sterimed, the worldwide specialist in infection prevention packaging solutions, Meeschaert Capital Partners sells its stake to Sagard in the context of a secondary LBO in association with company management.

In June 2016, Meeschaert Capital Partners’ MidCap Fund, Sterimed’s majority shareholder, joined up with Thibaut Hyvernat and his management team to spin Sterimed off from the ArjoWiggins Group.

Since then, the company has posted strong growth, both organically and through three acquisitions. After purchasing ATH Medical in 2017, Sterimed acquired in September 2019 a first company outside France: Especialistas en Esterilizacion y Envase (Grupo EEE), a latin american, mexican-based, major player in sterilization packaging and infection prevention solutions, with around €25 million in revenue. The company is also in exclusive negotiations with a company in China, with revenue of approximately €15 million.

Completion of this third acquisition (expected in the coming weeks) will make Sterimed a global market leader in medical packaging with nearly €140 million in revenue, 900 employees, 8 production plants and 20 sales offices.

‹ Back to news

M&A team:

anne hiebler
managing director

erwan thébault
executive director

romain clerc
vice president

guillaume decombe